FPM welcomes new Chair of Education and Standards Committee
Find out more
FPM Awards 2022: Congratulations to our new Fellows, Members and Specialist Registrants
Posted on: Tuesday 28 June 2022
Author: FPM
We are very pleased to announce new Fellows (FFPM), Members (MFPM) and entrants to the specialist register this year.
Find out more about some of them:
Fellows FFPM
Dr Jonathan Liu
Jonathan qualified in Medicine from Imperial College in 2005, along with a Bachelor of Science degree in Management from the Imperial College Business School. Still currently a Member of the Royal College of Surgeons, with his last clinical post (in Trauma & Orthopaedics) at Addenbrooke’s Cambridge, in 2011 he made the move into the pharmaceutical industry.
Jonathan has now worked in Medical Affairs, in a variety of senior leadership and strategic positions over the past decade. Indeed, he has particular fond memories in his roles at Napp and AbbVie, and as Medical Director, UK & Ireland, for Seqirus, and also for UCB Pharma. In 2017, he attained his CCT in Pharmaceutical Medicine, is on the GMC Specialist Register as a Consultant in Pharmaceutical Medicine, and in 2022, he was made a Fellow of the Faculty of Pharmaceutical Medicine.
Jonathan is presently in his role as International Medical Affairs Director at Kyowa Kirin International, and is enjoying being accountable for delivering the International Medical Strategy, primarily focussing on Real-World Evidence Generation and Phase IV studies. In the designated therapy area, he currently leads a Post-Authorisation Safety Study (PASS) and the largest & longest-running Registry ever in the world, and in collaboration with a hearty quorum of leading expert physicians in the field, has published over 17 articles to date in 2022.
During his time in his pharmaceutical career, Jonathan has worked and helped launch new drugs in the therapeutic areas of analgesics, respiratory, hepatology, vaccines, metabolic bone & monoclonal antibodies, and Rare Diseases.
Outside work, Jonathan enjoys playing golf, tennis, football, and squash, spending time with his wife, and watching his son & daughter play cricket in the sunshine.
Dr Temitope Adeloye
Tope is a Senior Research Physician, Principal Investigator (PI) and Head of Pharmacovigilance (PV) at Hammersmith Medicines Research (HMR). She is accredited by the MHRA as a PI for First-in-Human (FIH) studies.
In 2008, she did a BA in Biological and Biomedical Sciences/Pharmacology. She qualified in medicine, University of Cambridge, in 2011. After obtaining her medical degree, she spent 4 years working in the NHS as a junior doctor, gaining experience in a variety of medical and surgical specialties. She joined HMR in 2015 as a Screening and Research Physician. In 2019, she passed the Diploma in Pharmaceutical Medicine (DPM) with Distinction and in 2020, she completed her Pharmaceutical Medicine Specialty Training (PMST).
Since joining HMR, Tope has been investigator or co-investigator for many early-phase clinical studies of small molecules or biological products. She has worked on a wide range of studies, including FIH, PET, bridging, bioequivalence, drug-drug interaction, thorough QT, and studies involving administration of vaccines or radioactive compounds. She also set up within HMR a dedicated PV service to support PV operations for clinical trials.
Tope is a Visiting Lecturer in Clinical Pharmacology, Barts Hospital Medical College and Queen Mary University, London, for the MSc course in early drug development.
She has written or co-authored several papers on clinical pharmacology & drug development.
Dr Daniel Jabbari
In 1994, Daniel received his MD from Iran’s Shiraz University of Medical Science. In 2007, He joined the NHS and gained expertise in a variety of hospital specialties, including GP training. He moved to the pharmaceutical industry in 2014 and has worked in various stages of clinical development since then. He holds a CCT in pharmaceutical medicine and work for Rickett Company as a Lead Clinical Research Physician and a senior Manager. Clinical development and clinical pharmacology are two areas in which he is particularly interested.
Dr Anand Nayudu
Anand Nayudu graduated in Medicine, Master of Clin Pharm, CCST in Pharmaceutical Medicine, Fellow of Pharmaceutical medicine, and on GMC Specialist register. He has held various clinical responsibilities in Acute Medicine, Respiratory medicine, Pediatrics, and Urology.
Joining medical research in the pharmaceutical industry was a journey from abstract inspiration to reality. This was instilled by his Dean and professor Neelima Shirsagar at BYL Nair Hospital during his early medical school days. However, he did not know how and where to begin. He has started his career in India with many unknowns in the industry with vaccine development, and later in the UK working on therapeutic drug development in various disease areas in the last 15 years particularly in Oncology in all phases with a special focus on early exploratory development. This specialty has done wonders – this is essentially the science of ‘Revealing the Medicine within the Molecule’. He has a special interest in combination therapies i.e. biological and small molecules and antibody-drug conjugates. He is feel very thrilled that he had the opportunity to be at the forefront of advancing medicine and bringing new medicines to patients.
He has worked in Bharat Biotech, Servier, Roche, Pfizer, and Eisai, where I have contributed to several exciting drugs and successful programs (Small molecules and Monoclonal) in exploratory development as well as registration studies in Oncology namely Anti CSF1R, Anti EGFR, CDK 4/6 inhibitor – Palbociclib, and β catenin inhibitor. He was awarded the EU-Young scientist award by EU-DIA in 2011.
Looking back he feels very thrilled to have chosen Pharmaceutical Medicine as his specialty. He had received tremendous support from his parents to explore this path and he hopes to have made them proud.
Outside work he enjoys spending time in the garden, and cycling.
Dr Nick Probert
Dr Probert made the transition from Surgery to Pharmaceutical Medicine in 2014, taking on a role in clinical research as an investigator. His background in orthopaedics, neurology and pain management was well suited to providing expertise to these areas of clinical research. Since then, he has been involved in approximately 100 phase 1-4 studies and several molecules have gone to market. He has worked in dedicated phase 1 units on First-in-Human studies and late phase Site Management Organisations. He has been a UK Chief Investigator, including a phase 3 programme for a big-pharma company. He was a medical leader in a team which won global awards in clinical research whilst working for AES (Advanced Enrolment Solutions), beating over 100 sites to the top award.
He completed PMST and gained the Diploma in Pharmaceutical Medicine in 2019 and became a member of the Faculty.
He joined Proveca in 2019 and is now Head of Medical Affairs for the company which specialises in developing and licensing medicines for children.
He is naturally passionate about personal development of his teams and has mentored and trained pharmaceutical physicians to climb the career ladder. He regularly performs GMC appraisals for FPM and non-FPM pharmaceutical physicians.
Dr Maciej Zatonski
Dr Zatonski is a specialist ENT Surgeon and a pharmaceutical physician and holds a PhD in Head and Neck Oncology. He has transitioned to the pharmaceutical medicine in 2014 focusing primarily on vaccines R&D, preventive medicine, access to vaccines and implementation of vaccination programmes in the UK and global roles. Dr Zatonski is dedicated to supporting physicians in the pharmaceutical industry as an educational supervisor, examiner and appraiser. His commitment to developing others involves lecturing at key UK universities, his contributions to the new PMST curriculum, and through managerial and leadership roles that he has held in the industry.
Members (MFPM)
Dr Nayan Chaudhari
Nayan is a pharmaceutical physician with an MD. He has demonstrated skills related to clinical development in the global pharma industry and academic settings that include providing medical and scientific strategic inputs to the design, execution, monitoring, and reporting of clinical trials for more than 5 years. He has achieved a Diploma in Pharmaceutical Medicine (DPM) from the Royal Colleges of Physicians and Surgeons after finishing his senior residency (DM) in Clinical Pharmacology at the prestigious Seth GS Medical College and KEM Hospital, Mumbai. He previously worked as an Assistant Professor (Clinical Pharmacology) at KEM Hospital and as a Scientist-D at the ICMR’s Advanced Centre for Product/Drug Development in New Delhi. He has been a part of various pharma-sponsored as well as investigator-initiated clinical trials as a co-investigator or internal monitor in various therapeutic areas across all phases of clinical trials. He has also led multiple local and national initiatives to mentor/coach and scientifically train undergraduate and postgraduate medical students and faculty in various domains of drug development, including research methodology, in the past. He is currently working on early phase oncology clinical trials in various indications in Novartis’ Global Drug Development Office in the capacity of Clinical Scientist/Clinical Research Physician. His areas of interest include: Portfolio Strategy, Data Science tools, Clinical Development and allied areas like Research Ethics, Innovation in Clinical Trial methodology, etc. Outside of work, he enjoys playing badminton, reading history and psychology, and gardening.
Dr Shaun Flint
Shaun Flint trained in Australia as a nephrologist before moving to Cambridge in 2010, where he undertook a translational medicine PhD as part of the GSK and Wellcome Trust supported Translational Medicine and Therapeutics programme. During this time he also developed a subspecialty interest in renal and rheumatic autoimmune disease. He joined GSK in a translational medicine role in 2016, and joined the Pharmaceutical Medicine Specialty Training programme shortly thereafter. When he left GSK in 2022 he was a Group Leader within the Discovery Medicine Group. He is currently working as a Clinical Development Physician with Vifor Pharma, based in Zurich.
Dr Harriet Gray Stephens
Harriet obtained her medical degree from the University of Oxford, before completing foundation and core training to become an anaesthetics and intensive care registrar. Since 2019 Harriet has worked in the pharmaceutical industry firstly in late phase and more recently in early phase clinical research in large pharma. Following completion of the DPM exam, has moved to work with Boyds Consultants and is currently undertaking her executive MBA at Cambridge University.
Dr Rob Greenhalgh
Rob has achieved Membership by completion of the FPM Diploma in Human Pharmacology programme.
Rob holds degrees in both Biochemistry (2003) and Medicine (2010) from The University of Manchester, UK. Prior to his medical training he undertook molecular oncology research in the US and UK, with a focus on growth factor signaling. Following his medical hospital training he gained Membership of the Royal College of General Practitioners, practicing in this area for several years. In 2017, Rob joined industry at a CRO early phase clinical research unit, with a focus on first-in-human studies. He successfully completed the Diploma in Human Pharmacology programme with a wide portfolio of early phase studies, benefitting greatly from the mentorship provided by his FPM supervisor. Rob now works in clinical development for a pharmaceutical company applying his medical, scientific and clinical research experience to bring novel medicines closer to patients.
Dr Samina Hussain
Samina Hussain is a Patient Safety Physician with over 12 years of experience in Patient Safety, covering both early development and post-marketing products in drug development. After receiving her medical education, Samina explored various career options while working as a medical officer in a hospital and a diagnostics company, as a medico-legal expert in a law firm, and finally landing in Patient safety. She took the less-taken path into the pharmaceutical industry, at a time when little was known about the industry in India.
She started her pharmaceutical career in 2010 in a CRO working for Bristol-Myers Squibb, and later made her way to Novartis where she spent almost a decade first working as a Medical Safety Writer, and subsequently a Safety Physician, working in the Immunology therapeutic area. She quickly moved up the ladder and was promoted to Global Program Safety Lead (Director).
At Novartis, Samina was the Global process owner for causality assessment and medical assessment comments for ICSRs, and was involved in SOP ownership and training. She has been at the forefront of numerous audits and inspections, including being interviewed by auditors from various health authorities and license partners, responding to findings, and implementing CAPAs globally. Samina has also been instrumental in conducting several workshops for safety physicians and medical writers on PBRERs (assessment of safety signal/risk and presentation of data) at Novartis and many vendor sites.
Samina is currently a Senior Patient Safety Physician at Boehringer Ingelheim in Germany, where she is working on early clinical development (Phase 2 and 3) for compounds in Obesity and NASH. She is also managing a team of external physicians in a CRO that support Boehringer Ingelheim in various signal management activities.
Samina is a public speaking enthusiast, and an Ex-Toastmaster, and has completed Advanced Communicator and Leader levels.
Dr Yibin Kong
Yibin was trained in gastroenterology and holds a doctorate degree in hepatology. He joined the pharmaceutical industry in 2013 and has experienced roles in Medical Affairs and Clinical Development in oncology TA at local, Asian-Pacific and multi-regional levels. After relocating to Japan, he completed training in pharmaceutical medicine through JAPhMed. Yibin is now Medical Advisor in Oncology Medical Affairs at MSD Japan.
Dr Anu Koshy-Delaffon
Born and raised in Germany as a daughter of Indian parents, I came to the UK in 2005 and enrolled into the PMST in 2015. Completing the CCT and becoming a MFPM is a milestone in my professional and personal life and I wholeheartedly thank Him. I sincerely thank my family, especially my husband Vijay and my 3 beautiful kids Alyssa, Micael and Rafael for giving me the space and support to achieve this. My genuine gratitude is extended to my educational and pharmaceutical supervisers and of course Konrad for mentoring and supporting me all the way. Thank you!
Dr Luke Kuttschreuter
Dr Luke Kuttschreuter currently works at Pfizer Oncology as a medical affairs manager, and is based in Oxford, UK. Luke attended medical school at the University of Cape Town, South Africa and went on to begin his training in anaesthetics with a specific interest in the peri-operative physiology in oncology patients. Luke then moved to the UK to complete a MSc in pharmacology at the University of Oxford and held a clinical research fellow post at the Oxford Early Phase Clinical Trial Unit, before moving to Pfizer. Luke’s passion is in creating new, patient-centric approaches to clinical development and real-world data for which he has pioneered a number of innovative projects within the oncology team. In his free time, Luke loves to cycle and spend time watching a good Marvel movie with his partner, Sophie, and their two puppies.
Dr Lamine Soumahoro
Public Health Physician with 20 years industry experience in various medical affairs roles and clinical R&D roles at country, region and global levels, from late stage development to lifecycle management.
I supported several products launches as well as Phase III and IV local clinical studies and led scientific engagements with KOLs, Institutions and Ministries of Health for new vaccine’s introduction into National Immunization Programme.
Also led several patient engagement activities in collaboration with Patient Advocacy Groups to ensure to ensure their needs are the focus.
Hold MD degree from University of Abidjan, a Diploma in Pharmaceutical Medicine form Free University of Brussels and completing a Master of Sciences in Epidemiology form London School of Hygiene and Tropical Medicine.
Live in Wavre in Belgium, father of 3 adolescents 18, 16 and 13 years old, outside of work I like spending time with my family and doing sport outdoors (walking and running).
Dr Saket Thaker
- Pharmaceutical Physician with over 10 years of rich experience through Industry and Academia
- Currently working with Sanofi as Senior Clinical Research Medical Advisor and Clinical Safety Lead for India and South-East Asia
- Prior affiliations with renowned organizations such as Roche and Dr Reddy’s Laboratories
- Worked as Medical expert in numerous global and local clinical trials (phase I to IV) and real-world evidence (RWE) studies involving new chemical entities (NCEs), new biological entities (NBEs) and vaccines
- Experienced in designing clinical trial protocols, informed consent documents (ICDs), regulatory briefing books and deficiency responses for agencies i.e. US-FDA, EMA
- Medically and scientifically trained in therapeutic areas such as oncology, neurology, hematology, immunology, infectious and metabolic diseases
- Several national and international Publications and Presentations
- Recipient of numerous professional and academic awards
- Aspiring to enhance career in Global Clinical Development
- Enjoys writing, cycling and meditation to unwind and relax
Entrants to the Specialist Register
Dr Niroshini Naicker
Dr Niroshini Naicker is a dual specialised physician in Clinical Oncology and Pharmaceutical Medicine, currently working as a Clinical Director within Late Stage Oncology Clinical Development.
She received her medical degree from University of Natal Medical School, South Africa and completed her core medical training at the King Edward VIII teaching hospital and Greys Hospital in Pietermaritzburg, South Africa in 2001. After gaining clinical experience across UK hospitals, she returned to Cape Town, South Africa where she completed her Clinical Oncology training at Tygerberg Hospital, Cape Town. She holds the Fellowship of the College of Radiation Oncologists South Africa and is on the specialist register for Clinical Oncology on the Health Professions Council of South Africa since 2008. In the, UK she has worked as a Clinical Oncologist across multiple solid tumour teams in NHS hospitals, incl. The Christie (Manchester), Queen Elizabeth Hospital (Birmingham), Royal Surrey County Hospital (Guildford) and Guy’s & St Thomas’ (London).
In 2015 Nirosh joined the pharmaceutical industry within the medical affairs division working as an Oncology Medical Advisor on HTA applications, PIM/EAMs programmes; generation and publication of Real-World Data studies and practiced as a ABPI/IPHA final medical signatory. Nirosh commenced her post-medical specialist training in pharmaceutical medicine through the Faculty of Pharmaceutical medicine in 2016. She was successful in the FPM’s Diploma of Pharmaceutical Medicine examination, at first attempt, in 2019, and completed PMST training in February 2021.
Since June 2020, Nirosh moved into the discipline of Clinical Development. She is a Clinical Director and Medical Monitor for 2 Global Oncology Clinical Trials.
In March 2021, Nirosh entered the GMC specialist register in Pharmaceutical Medicine.
Outside of work, she enjoys travelling, arts and culture activities, hiking, painting and yoga.
Dr Ugochukwu Stephanie Igwe
Stephanie was born and raised in Eastern part of Nigeria, West Africa, obtained her medical degree (MBBS) in the Eastern part of Nigeria before moving to the UK 2005.
She worked in the NHS where she acquired her core medical training in general medicine before moving to the industries in 2013.
She started her career in the industry as a Sub Investigator in early phase clinical trials including First in human trials, has worked in few CROs before moving to GSK in 2017 as Clinical trial physician and Principal investigator in early phase clinical trials.
Stephanie is happily married with 4 children and enjoys travelling and charity work.
She wishes to use this opportunity to thank her husband Nnanna and her 4 children for all their support during her PMST training. Also, a huge thank you to all the people that played a key role to her achievements, Her educational supervisors, her line managers and her colleagues at work for all their support and assistance. A special thanks to Prof. J Ritter for your mentorship and support. I appreciate you all.
Dr Chigo Munthali
Chigo graduated with an MBBS degree from University of Malawi, College of Medicine in 2007. After completion of her foundation programme, she moved to the UK and joined the NHS in 2010. While in the NHS, she worked in various surgical subspecialties. In 2017, she joined the pharmaceutical industry as an investigator and has worked in both early and late phase clinical research. She attained a Diploma in Pharmaceutical Medicine in 2020 and completed her Pharmaceutical Medicine Specialist Training in 2022.
Chigo also holds a MSc degree in Tropical and Infectious Diseases from Liverpool School of Tropical Medicine with distinction and she has recently joined AstraZeneca’s late-stage clinical development team for Vaccines and Immune Therapy as a Global Clinical Development Medical Director.
Dr Shaun Flint
Shaun Flint trained in Australia as a nephrologist before moving to Cambridge in 2010, where he undertook a translational medicine PhD as part of the GSK and Wellcome Trust supported Translational Medicine and Therapeutics programme. During this time he also developed a subspecialty interest in renal and rheumatic autoimmune disease. He joined GSK in a translational medicine role in 2016, and joined the Pharmaceutical Medicine Specialty Training programme shortly thereafter. When he left GSK in 2022 he was a Group Leader within the Discovery Medicine Group. He is currently working as a Clinical Development Physician with Vifor Pharma, based in Zurich.
*Dr Shaun Flint is awarded Membership (MFPM) and is an Entrant to the Specialist Register
Dr Marianna Lalla
Dr. Marianna Lalla, MD PhD MPH CCT(PharmMed., PeadSurg.), has a clinical and academic background with over 20 years clinical experience in surgery and different fields of medicine, medical devices, clinical trials and pharmaceutical medicine. During her work in both CROs and Pharma, Marianna has led or been instrumental in 90 clinical trials ranging from early-phase translational projects to global Phase 3 studies and has provided medical inputs for regulatory interactions with an array of regulatory bodies (MHRA, EMA including COMP and PDCO, FDA, PMDA, CFDA). She has established key-opinion leader networks and high value research collaborations for a variety of different products. Most recently, she worked as Global Clinical Development lead in Translational Medicine at UCB, responsible for the global development of multiple clinical projects.
Marianna originally trained as a paediatric surgeon, has a PhD in Medicine which utilised biomechanical methods after surgical techniques, and a Master of Public Health with a thesis in health economics. In relation to her previous training as paediatric surgeon, she obtained a European Fellowship in Paediatric Urology. She also holds a Certificate in Pharmacoepidemiology and Pharmacovigilance from the London School of Hygiene and Tropical Medicine, and a Diploma in Pharmaceutical Medicine, as part of her specialty training in Pharmaceutical Medicine. Marianna is GMC specialist registered since 2009 (now under pharmaceutical medicine). She joined OxSonics as Chief Medical Officer in June 2022.
Dr Michael Holmes
Over the course of his career, Michael has sought to harness the power of human genetics and large biobanks to better understand the causes of disease and identify potential therapeutic targets. Following practising as a hospital clinician in the NHS, Michael studied towards an MSc in Epidemiology from LSHTM and PhD in Epidemiology from UCL. He subsequently held faculty positions at University of Pennsylvania and University of Oxford where he was Assistant and Associate Professor, respectively. During his specialist training in Pharmaceutical Medicine, Michael was awarded the inaugural Peter Stonier prize for his vision of pharmaceutical medicine.
Michael has recently taken up a position as Principal Scientist within 23andMe (California, USA) where he works in the Genomics R&D and Therapeutics groups. He is involved in harnessing insights from the millions of 23andMe users to integrate polygenic risk scores for precision medicine and in genomically-guided drug development. Michael’s academic career has been supported by fellowships from the Medical Research Council, UK and British Heart Foundation, UK.
Michael is extremely grateful to his mentor Prof George Davey Smith (University of Bristol) for unwavering continued support and intellectual collaborative pursuits and Dr Christina Reith (University of Oxford) who was an exceptional Educational Supervisor for the FPM’s Pharmaceutical Medicine Specialty Training. He is eternally indebted to his wife.
Dr Ayman Nassar
Dr Nassar is a pharmaceutical medicine specialist with 16 years of clinical practice experience in General Medicine and Oncology. His clinical interests were focused on improving cancer patient care and experience. Later during his practice he took a special interest in the emerging Immunotherapy field. In addition to his clinical experience, Dr Nassar holds a post graduate diploma in clinical education, and taught at Exeter Medical School as an honorary Fellow for 8 years.
He joined the industry in 2016, working in several departments in medical affairs where his passion for medical education and patient-centred high quality care led him to deliver a number of highly attended and well received national educational conferences. Dr Nassar also initiated several real world data studies, resulting in the development of clinical decision aid tool for oncologists.
Having practiced medicine in different countries and witnessed inequality in access to clinical care he is motivated and driven by improving equality in health care.
Dr Nassar currently works in clinical development, focussing on Lung cancer late drug development studies and is exploring various aspects of drug development processes, regulatory interaction and safety management.
Dr Victoria Parker
Dr Victoria Parker trained at the University of Cambridge and Imperial College for her primary medical qualification and obtained a CCT in Diabetes, Endocrinology and General Internal Medicine in 2016. During her training she undertook a Wellcome Trust research training fellowship and PhD in Clinical Biochemistry investigating rare mosaic overgrowth disorders due to dysregulated PI3K-AKT signalling. She joined AstraZeneca 6 years ago and is currently a Senior Group Director in early clinical development specialising in cardiovascular, renal and metabolism programs and an honorary consultant in Diabetes and Endocrinology at Cambridge University Hospitals NHS Trust. She completed her Pharmaceutical Medicine CCT in 2022.
Dr Urmi Shukla
Urmi qualified as physician in 2005 from Guy’s, King’s and St Thomas’ Medical School (UK) and was a speciality trainee in Obstetrics and Gynaecology.
During her training as a research fellow in Assisted Reproduction, she contributed to National guidelines and presented her research at National and International conferences. She also holds a first-class BSc in Maternal and Fetal Physiology from King’s College, London.
Having left the NHS in 2014 she joined a CRO as a research physician and was PI on a number of phase 2 and 3 clinical trials, across a range of therapy areas. Following on from her first medical affairs role in 2015 at Pfizer, Urmi joined Sanofi Genzyme as the UK & Ireland Oncology team lead in 2018. Her extensive oncology experience was further broadened during her role as the EMEA medical director in Eisai for breast and endometrial cancer. Urmi is currently in the GSK oncology clinical development team as medical director for a First in Human Trial in solid tumours. She has also been an author on posters and manuscripts during her time at GSK.
She is not only driven about her own development, but also developing and supporting others having mentored via the Healthcare Businesswomen’s Association and has post CCT, enrolled to become an ES and support PMST trainees through their journey.
Lastly, she is very grateful to the great organisations and people that have helped her complete her PMST training and a special thanks to her husband Ajay for his continued support- thank you!’
